National Heart Failure Awareness Week

The Canadian Heart Failure Society (CHFS), together with our committee of cardiovascular professionals and partner organizations, is pleased to announce the 3rd annual National Heart Failure Awareness Week campaign scheduled for May 3-9, 2021.
 
As the impact of heart failure (HF) continues to grow across Canada and throughout the world, it is becoming increasingly important to engage health care providers in raising awareness among patients and their families. With the aim to improve the quality of life for people living with HF, this year’s campaign will focus on self-management and self-care in a virtual world.

We encourage you to promote Canadian Heart Failure Awareness Week by engaging in activities to raise awareness around HF. To support you in these efforts, an updated TOOLKIT of materials is now available. More information about materials, webinars, how to follow us on social media and how to access resources can be found below. 

Toolkit Materials

A poster, patient handout and toolkit for social media engagement are now available for download.

Webinars 

Information and details about patient-facing webinars and provider-facing webinars planned for the week of May 3-9, 2021 can be found below under Tools and Resources - check it out!

Social Media

You can follow @CanHFSociety on Twitter, the hashtag #HeartFailureWeekCan, and add a Twibbon to your profile picture.  

We encourage you to promote these activities while continuing to maintain physical distancing. Thank you in advance for your participation and engagement.

Sincerely,

Dr. Anique Ducharme, MD, MSc, FRCP
Professor of Medicine, Université de Montréal 
Director, Heart Failure Clinic 
Montreal Heart Institute, Research Center
President, Canadian Heart Failure Society  

 

 

Tools and Resources

Documents

Graphics 

Click here to access graphics to bring your posts to life. 

Webinars & Conferences

There are currently no upcoming webinars or conferences. 

Special Thanks

This event is made possible through the support from Astra Zeneca, Bayer Inc., Boehringer Ingleheim-Lilly, Novartis Canada, and Servier Canada.